Results 121 to 130 of about 3,103 (172)

Effect of Elexacaftor/Tezacaftor/Ivacaftor Treatment on Extrapulmonary Complications of Cystic Fibrosis. [PDF]

Adv Ther
Geiger JM, Brady BL, Lew CR, Jennings M, Mo C, Van Brunt K, Dezube R.   +6 more
europepmc   +1 more source

Predictive capacity of paediatric nasal epithelial cells in sequential CFTR modulator therapy. [PDF]

Thorax
Fawcett LK, Chew ZA, Schneider-Futschik EK, Allan KM, Patel HR, Jaffe A, Waters S.   +6 more
europepmc   +1 more source

Quantitative Systems Toxicology Predicts Ivacaftor-Induced Oxidative Stress Contributes to CFTR Modulator Hepatotoxicity. [PDF]

Clin Pharmacol Ther
Shi A, Cornwell C, Yang K, Beringer PM.
europepmc   +1 more source

Changes in sputum viscoelastic properties and airway inflammation in primary ciliary dyskinesia are comparable to cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy. [PDF]

Eur Respir J
Nussstein H, Urbantat RM, Fentker K, Loewe A, Duerr J, Haji M, Doellinger F, Stahl M, Graeber SY, Gradzielski M, Röhmel J, Mertins P, Schaupp L, Mall MA.   +13 more
europepmc   +1 more source

Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard. [PDF]

BMJ Open Respir Res
Evans IES, Smith D, Henderson D, Riddles T, Masel P, Moore V, Burke AJ, Thomson RM, Reid DW.   +8 more
europepmc   +1 more source

Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Italy: A Retrospective Study from a Cystic Fibrosis Center. [PDF]

Pulm Ther
Cipolli M, Thorat T, Pafundi PC, Roggeri A, Roggeri DP, Rossi C, Pintani E, Meneghelli I, Lucca F, Fratoni A, Vega-Hernandez G.   +10 more
europepmc   +1 more source

Persistence of lung hyperinflation and small airway dysfunction in school-aged children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: results from the real-world MODUL-CF study. [PDF]

ERJ Open Res
Colin L, Delaup V, Le Bourgeois M, Neve V, Wizla-Derambure N, Ioan IC, Tatopoulos A, Kieffer S, Blonde A, Bokov P, Houdoin V, Le Clainche L, Barzic A, Ohlmann C, Toin T, Perrin T, Coutier L, Abou Taam R, Bonnel AS, Rignani A, Feghali H, Bui S, Fayon M, Letierce A, Sermet-Gaudelus I, Reix P.   +25 more
europepmc   +1 more source

Impact of Elexacaftor-Tezacaftor-Ivacaftor on Gastrointestinal Symptoms, Intestinal Ultrasound, and Pancreatic Stiffness in Cystic Fibrosis. [PDF]

Clin Transl Gastroenterol
Fraquelli M, Piagnani A, Corti F, Lanfranchi C, Casazza G, Colombo C.   +5 more
europepmc   +1 more source

Impact of COVID-19 and CFTR Modulators on Cystic Fibrosis: A Real-World Analysis of Care Patterns. [PDF]

Pediatr Pulmonol
Hinton AC, Sears EH, Lopez-Pintado S, Zuckerman JB.   +3 more
europepmc   +1 more source

Impact of Elexacaftor-Tezacaftor-Ivacaftor on Quality of Life in Children With Cystic Fibrosis. [PDF]

Pediatr Pulmonol
Kümmerli S, Elviro CF, Regamey N, Mornand A, Faouzi M, Rochat I, Blanchon S.   +6 more
europepmc   +1 more source